Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab

Keeping Track Feature image
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers